As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...
Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock ...
French multinational pharmaceutical company Sanofi has commenced the shipping of BEYFORTUS (nirsevimab-alip) to the US, ...
French pharma major Sanofi today revealed it is shipping Beyfortus (nirsevimab-alip) 50mg and 100mg Injection doses in the ...
Sanofi (SNYNF, SNY) said it is shipping BEYFORTUS 50mg and 100mg Injection doses in the US to private healthcare providers and to the ...
16, 2024 /PRNewswire/ -- Sanofi is shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and ...
The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centres for Disease Control and ...
French multinational pharmaceutical company Sanofi has commenced the shipping of BEYFORTUS (nirsevimab-alip) to the US, targeting both private healthcare providers and the Centers for Disease ...
16, 2024 /PRNewswire/ -- Sanofi is shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and Prevention ...
Company planning for every eligible baby in the US to have access to BEYFORTUS <li /> New BEYFORTUS filling line approved by the ...